Barclays’s Evolent Health EVH Stock Holding History

Barclays’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$3K	–	7040
2018 Q3	$3K	Buy	+100	New	+$2.38K	﹤0.01%	6881

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Barclays's EVH Position: Q2 2026 in Review

Barclays reduced its Evolent Health (EVH) stake by 3.6% in Q2 2026, selling an estimated $10.3K and leaving 71,488 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #3355.

Barclays first reported a position in EVH in Q2 2016 and has held it in 41 quarters since. The position peaked at $12.7M in Q2 2025. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

Barclays held 71,488 shares of Evolent Health worth $387K as of Q2 2026.
Barclays sold 2,692 Evolent Health shares in Q2 2026, an estimated $10.3K.
Evolent Health made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3355 holding.
Barclays first reported a position in Evolent Health in Q2 2016 and has held it in 41 quarters since.
Barclays's Evolent Health position peaked at $12.7M in Q2 2025.
199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.